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Abstract
Background: Experimental infection of the mouse brain with murine CMV (MCMV) elicits neuroimmune responses that
terminate acute infection while simultaneously preventing extensive bystander damage. Previous studies have determined
that CD8
+ T lymphocytes are required to restrict acute, productive MCMV infection within the central nervous system (CNS).
In this study, we investigated the contribution of humoral immune responses in control of MCMV brain infection.
Methodology/Principal Findings: Utilizing our MCMV brain infection model, we investigated B-lymphocyte-lineage cells
and assessed their role in controlling the recovery of reactivated virus from latently infected brain tissue. Brain infiltrating
leukocytes were first phenotyped using markers indicative of B-lymphocytes and plasma cells. Results obtained during
these studies showed a steady increase in the recruitment of B-lymphocyte-lineage cells into the brain throughout the time-
course of viral infection. Further, MCMV-specific antibody secreting cells (ASC) were detected within the infiltrating
leukocyte population using an ELISPOT assay. Immunohistochemical studies of brain sections revealed co-localization of
CD138
+ cells with either IgG or IgM. Additional immunohistochemical staining for MCMV early antigen 1 (E1, m112–113), a
reported marker of viral latency in neurons, confirmed its expression in the brain during latent infection. Finally, using B-cell
deficient (Jh
2/2) mice we demonstrated that B-lymphocytes control recovery of reactivated virus from latently-infected
brain tissue. A significantly higher rate of reactivated virus was recovered from the brains of Jh
2/2 mice when compared to
Wt animals.
Conclusion: Taken together, these results demonstrate that MCMV infection triggers accumulation and persistence of B-
lymphocyte-lineage cells within the brain, which produce antibodies and play a significant role in controlling reactivated
virus.
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Introduction
Human cytomegalovirus (CMV) is the most significant
infectious cause of congenital anomalies of the central nervous
system (CNS), such as microcephaly and periventricular calcifica-
tion. CMV is also the most frequent opportunistic cerebral
infection in acquired immunodeficiency syndrome (AIDS) pa-
tients, in whom it can cause encephalitis and encephalopathy. In
immunocompetent patients, immune control mechanisms effec-
tively prevent overt disease and terminate viral replication.
However, ultimate clearance of the viral genome is not achieved.
Instead, like other herpesviruses, CMV remains life-long at specific
sites. During nonproductive, latent infection viral gene expression
is minimized to a small subset of genes [1]. The productive viral
replication cycle can be initiated from this latent infection and
result in transient phases of virus shedding and recrudescent
disease. In immunocompromised patients, recurrence of human
CMV infection frequently leads to overt manifestations of disease
[2].
Our previous studies have shown that subsequent to intracer-
ebroventricular (i.c.v.) infection with murine CMV (MCMV), viral
brain infection is predominant in cells that line the periventricular
region. These periventricular cells were subsequently identified as
nestin positive, neural stem cells [3,4]. The infection spreads into
the parenchyma only in the absence of an effective CD8 response
[5]. Evidence suggests that neural stem cells which escape the lytic
phase of infection may differentiate into neurons that express a
latency-associated antigen MCMV E1 (m112–113) [6]. These
studies utilized neonatal mice to show preferential expression of E1
in latently-infected neurons. Establishment of latency after
clearance of acute infection and the potential to reactivate to
infection are key features of herpesvirus pathogenicity [7].
Reports using the MCMV model have established the
importance of CD8
+ T-cells for control of primary infection
[8,9]. Likewise, previous studies from our laboratory have shown
that CD8
+ T-cells play an important role in controlling acute brain
infection and these antigen-specific cells persist even during the
absence of active viral replication [10]. A number of previous
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presence of viral genomes as well as immune cells in the brain,
particularly T and B-lymphocytes [11,12,13]. These studies have
shown that B-cell deficient mice were unable to control viral
clearance from cortical and hippocampal neurons [14,15].
However, little is known about the presence and role of B-lineage
cells during MCMV brain infection.
In other models, it has been demonstrated that humoral
immune responses driven by B-lymphocyte lineage cells can persist
in nonlymphoid tissues following inflammatory insults. Neurobor-
reliosis, neurosyphilis, subacute sclerosing panencephalitis, and
multiple sclerosis are all characterized by CNS accumulation of B-
lymphocyte lineage cells such as antibody secreting cells (ASC) and
elevated immunoglobulin in cerebral spinal fluid [16,17]. During
experimental CNS infections by RNA viruses such as Sindbis,
Semliki Forest, rabies, and neurotropic coronaviruses, ASC appear
to play a local protective role [18,19,20,21]. Despite several
reports describing the vital role that antibodies play during
MCMV infection in peripheral organs, it remains to be
determined whether a microenvironment which fosters humoral
immune responses in the brain is created following MCMV
infection and whether this response plays a significant role in
controlling viral infection. In the present study, we investigated the
kinetics of B-lymphocyte lineage cell recruitment into the brain,
their ability to produce virus-specific antibodies, and their role in
controlling viral infection.
Results
B-cell recruitment into the brain
Previous studies from our laboratory have shown that following
MCMV brain infection, there is a clear distinction in the type of
peripheral immune cell infiltration between the acute and chronic
phases of disease. While innate components like neutrophils and
macrophages constituted the majority of the cellular infiltrate
during acute phase, persistence of antigen specific CD8
+ T-cells
was evident at 30 d post-infection (p.i.). In this study, multi-color
flow cytometry was used to phenotype lymphocyte subpopulations
infiltrating the brain at various time points p.i. Brain-infiltrating
mononuclear cells were isolated on a percoll gradient as described
in the methods. These isolated cells were subsequently immuno-
stained using the markers CD45, CD11b, CD3 and CD19. B-cells
expressing the CD19 marker were identified among the
CD45
(hi)CD11b
+ population, which represent cells of myeloid
origin. At 7 d p.i., 2.85% of the cells were reactive to CD19 and
this population increased to 3.93%, 5.04%, and 8.99% at 14, 21
and 35 d p.i., respectively (Fig. 1A). The absolute number of
CD19
+ cells was also determined. An increase in the number of
these cells was apparent starting at 7 d p.i. (1.1610
569.6610
3),
14 d p.i. (1.2610
568.5610
3), 21 d p.i. (1.7610
566.4610
3), until
30 d p.i. (2.4610
562.1610
4) (Fig. 1B).
Cytokines and B-cell survival factors play important role in
recruitment and retention of B-lymphocyte lineage cells in the
brain [13]. For this reason, we investigated the expression levels of
IL-21, a key cytokine implicated in B cell proliferation and
differentiation, which is predominantly secreted by CD4
+ T cells
[22]; B cell-activating factor of the tumor necrosis factor (TNF)
family (BAFF); and a proliferating-inducing ligand (APRIL), both
of which are considered to be B-cell lineage activating and survival
factors [23,24]. mRNA expression for IL-21 in infected brains was
markedly higher than uninfected controls at 7 d p.i. (,400 fold)
and at 30 d p.i., its expression was still detectable (,20 fold;
Fig. 1C). Correspondingly, mRNA levels for BAFF and APRIL
were also found to be elevated at 7, as well as 30 d p.i. Identifying
these factors at the time of B-cell presence suggests that survival
factors which play a crucial role in B lymphocyte retention are
present following MCMV brain infection (Fig. 1C).
To visualize this B-cell trafficking into the brain, we went on to
perform adoptive transfer experiments. Using a bioluminescence
imaging approach, we transferred MCMV-primed CD19
+ cells
from b-actin promoter-luciferase expressing transgenic mice into
B-cell deficient mice (Jh
2/2). Jh
2/2 recipient animals were given
5610
6 primed CD19
+ cells 1 d prior to viral infection. The
kinetics of CD19
+ lymphocyte infiltration into the brain was
examined longitudinally. Within 2 h of adoptive transfer,
luciferase-positive cells were detected in the spleen. Movement
of these CD19
+ cells into the brain was observed at 10 d p.i. in
Jh
2/2 mice (Fig. 1D).
Presence of plasma cells in the MCMV infected brain
Following the detection of CD19
+ cells in infected brains, we
assessed the presence of CD19
2CD138
+CD38
+ plasma cells
among the brain-infiltrating mononuclear cells. Cells isolated on
percoll gradients from infected brain tissue at various time points
were stained for CD45, CD11b, CD3, CD19, CD38 and CD138.
Those that expressed CD45
(hi)CD3
2CD19
2CD138
+CD38
+ were
phenotyped as plasma cells. Presence of these cells in the brain was
observed at all time points studied, ranging from 15.73%–24.69%
(Fig. 2A). The absolute number of CD19
2CD138
+CD38
+ cells
was found to peak at 7 d p.i. (6.6610
565.0610
4) and gradually
decline at the later time points studied, 14, 21 and 30 d p.i.
(5.9610
561.7610
4, 5.0610
562.1610
4 and 4.1610
563.3610
4,
respectively) (Fig. 2B). The presence of plasma cells in the brain
was also confirmed by immunohistochemical staining. Serial
coronal sections were collected from infected brains at 30 d p.i.
and were stained using Mabs against CD138. Persisting CD138
+
cells were detected around the ventricles (Fig. 2C, upper panel), as
well as within the cortex (Fig. 2C, lower panel).
Long-term persistence of antibody secreting cells
Phenotypic analysis demonstrated that CD138
+ plasma cells
persisted in MCMV-infected brains. In order to investigate
whether they were driving MCMV-specific humoral immune
responses, ASCs isolated from infected brains were subjected to
ELISPOT assay to detect MCMV-specific IgG production. At
30 d p.i., IgG-producing ASCs specific for MCMV were detected
in infected brains (103631 IgG ASC/10
6 cells). The presence of
ASCs was still evident, at 65 d p.i. (4465 IgG ASC/10
6 cells)
(Fig. 3A). To determine the tissue distribution of CD138
+IgG
+ or
CD138
+IgM
+ cells, we performed immunofluorescence staining.
Four weeks p.i., sections were stained for CD138
+, IgG, and IgM
expressing cells. In these studies, CD138
+ cells were found to be
co-localized with either IgG or IgM and were predominantly
detected in the subventricular zone, where MCMV actively
replicates during acute phase of the disease (Fig. 3B), but double-
positive cells were found in various brain regions including the
cortex.
Presence of latency-associated viral antigen
Previously, we have reported that active viral expression is not
detected at 30 d p.i., either by immunohistochemical staining for
MCMV-IE1 in brain tissue sections, or by mRNA real-time PCR
for MCMV-IE1 genome in total brain homogenates. Earlier
reports, using neonatal mice, suggested that the MCMV early
gene E1 (M112–113) product has a tendency to be retained in
neurons following MCMV-infection [25], especially during
prolonged infection [26]. These studies suggested that neurons
contain factors that drive promoter expression for this MCMV
ASCs in the Brain Control Reactivated MCMV
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products. In the present study, using adult mice, we confirmed that
MCMV-E1 expression does occur in neurons within latently-
infected brains. IE1 and E1 expression were both evident at 5 d
p.i. (Fig. 4 A, B), whereas only E1 expression was observed at 30 d
p.i., in both Wt and Jh
2/2 mice (Fig. 4, C–F).
B-lineage cells limit recovery of reactivated virus
Following the demonstration of latent viral protein in infected
brain sections, we then designed experiments to reactivate the
virus. Previous studies using an Ig m chain–deficient mouse, devoid
of B-cells and antibodies, revealed that antibodies are not required
for the resolution of primary MCMV infection, and latency is
established with the same kinetics as in seropositive controls
[27,28]. Using this model, studies have shown that virus could be
reactivated in various organs including, salivary glands, lungs and
spleen [29]. These findings suggested that B-cells, along with other
immune cells, play a vital role in preventing the recovery of
reactivated virus from different organs. However, the role of these
cells in the brain was not addressed. Using a similar mouse strain,
Jh
2/2, which fails to produce functional B-cells as they lack the
gene for the heavy chain joining region, we investigated the effect
of B-lineage cells on recovery of virus reactivated from latently
infected brain tissue. Latently infected brain tissue samples were
collected from Wt and Jh
2/2 and were processed as outlined in
the Fig. 5A. Slow-dividing, primary murine glial cells were used as
indicator cells for explant cultures. In addition, direct homoge-
nized tissue samples collected at 30 d p.i. were tested negative for
MCMV-IE1 genes in Wt and Jh
2/2 mice by real-time PCR assay,
indicating an absence of productive viral infection. 7–10 d post–
explant, murine mixed glial cultures were either stained for the
presence of MCMV-IE1 protein by immunohistochemistry or
prepared for real-time PCR. In these experiments, recovery of
reactivated virus was found to be significantly higher in the Jh
2/2
Figure 1. Entry and long-term persistence of B lymphocytes following MCMV brain infection. Single cell suspensions of brain tissue
obtained from MCMV-infected mice (2–4 animals) per time point were banded on a 70% Percoll cushion. Brain leukocytes were collected and labeled
with APC-conjugated Abs specific for CD45, Cy7-APC-labeled anti-CD11b, PE-CY7 anti-CD3, FITC anti-CD19 and analyzed using flow cytometry and
FlowJo software. A. Representative FACS plots showing the percentages of CD45
+CD19
+ B lymphocytes within the infiltrating CD45
(hi)CD3
2
population within infected brains at 7, 14, 21 and 30 d p.i.. B. FITC-labeled anti-CD19 Abs were used to determine the total number of CD19
+ B
lymphocytes within the infiltrating CD45
(hi)CD3
2 population. Data shown are mean (6SEM) absolute number of infiltrating cells pooled from 3
independent experiments. C. mRNA levels for B-cell trophic factors were measured in total brain homogenates at the indicated time-points. D.
Primed CD19
+ B-cells from b-actin promoter-luciferase transgenic BALB/c mice were transferred via tail vein injection into MHC-matched, B-cell
deficient (Jh
2/2) recipients 1 d prior to viral infection. Representative dorsal bioluminescence images of 2 saline-injected controls and 3 infected
recipient animals are shown at the indicated time-points.
doi:10.1371/journal.pone.0033143.g001
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leukocytes from MCMV-infected mice were obtained and analyzed at the indicated time points. Contour plots depicting percentages of CD38
+ and
CD138
+ double positive cells from the gated CD45hi population are shown. These cells also stained negative for CD3 and CD19. B. Data showing the
mean (6SEM) absolute number of cells within the infiltrating CD45
(hi)CD3
2CD19
2 population pooled from 3 independent experiments. C.
Immunofluorescent staining showing the distribution of CD138
+ plasma cells in both the ventricles and brain parenchyma at 30 d p.i. (magnification
206).
doi:10.1371/journal.pone.0033143.g002
Figure 3. CD138
+ ASCs persisting in the CNS produce antiviral antibodies. A. Frequencies of MCMV-specific ASCs persisting in the brain at
30 and 65 d p.i. as determined using ELISPOT. Data are presented as mean 6 SD of triplicates and are from two independent experiments. B.
Immunofluorescent staining of brain sections obtained from infected animals at 30 d p.i. for IgG and IgM co-localized with CD138 (magnification
206).
doi:10.1371/journal.pone.0033143.g003
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2/7 (28.6%), as detected by the presence of viral gene products in
the explant cultures (Fig. 5B).
Discussion
Although several studies have demonstrated humoral immune
responses in the CNS following infectious or inflammatory assault,
the persistence of B-lymphocyte lineage cells in the brain following
MCMV infection has not been reported. Our results demonstrated
B-cell recruitment into the CNS occurs early in the disease and
persists during latent infection. In addition, ASCs isolated from
brain were tested for MCMV-specific antibody production and the
significance of these cells in controlling infectious virus was
demonstrated using B-cell deficient animals.
The accumulation and retention of virus-specific ASC within
the CNS are hallmarks of many neurotropic viral infections.
Several studies have characterized the cytokines and chemokines
essential for recruitment and survival of T- and B-cells in the CNS.
In this study, we detected expression of B-cell trophic factors such
as IL-21, APRIL and BAFF. IL-21 is a type I cytokine that signals
through a receptor composed of IL-21R and the common cytokine
receptor c-chain [30]. Over the past decade, IL-21 has emerged as
a key cytokine for the differentiation of activated B lymphocytes
into plasma cells and, in consequence, for establishing and
maintaining Ab responses. IL-21 is produced mainly by distinct
T lymphocyte subsets. It has been established in studies using
human cells that mature plasma cells do not express IL-21
receptors, hence do not require IL-21 [22]. In our study, decreased
levels of IL-21 in the brain were observed at 30 d.p.i., when a
higher number of ASCs was detected. Similar findings have been
reported during other viral brain infections [13].
Previous studies from our laboratory utilizing HSV [31] and
MCMV [10,32] brain infection models have shown that T-cells
play a vital role in controlling infections in this immunologically
privileged site. Entry of peripheral immune cells into the brain is
essential for clearance of infectious virus [33] and previous reports
using RNA viruses have shown that IFN-c and anti-viral IgG are
required for this effect [14,21]. We have previously demonstrated
the accumulation and retention of virus-specific T-cells in the
brain following MCMV infection and these long-term persisting
cells were found to produce IFN-c upon ex-vivo stimulation with
viral peptides [10]. The recruitment of B-lineage cells into brain
has been shown to be dependent upon cytokine and chemokine
Figure 4. Latently-infected neurons expresses MCMV early 1 (E1, m112–113), but not immediate early 1 (IE1) antigen. Coronal murine
brain sections were prepared and stained for viral proteins at indicated time points. A. Detection of MCMV IE1 and B. E1antigens in wild-type mice
during acute infection (5 d p.i.), lower magnifications (206) demonstrate that MCMV is localized to cells surrounding the ventricles. C–F. Tissue slices
from infected brains were stained with an antibody to MCMV E1 during chronic infection (30 d p.i.). Cells positive for E1 antigen in the cortex and
hippocampus of wild-type (C), as well as B-cell-deficient (Jh
2/2) animals (D, E and F), are shown. Micrographs at higher magnification (406)
demonstrate the neuronal morphology of infected cells.
doi:10.1371/journal.pone.0033143.g004
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through CXCR3 [34].
Due to the inherent nature of herpesviruses to establish latency
it is imperative to identify host factors that restrict virus
reactivation in this vital organ. The role of B-cells has been well
established in restricting MCMV in other organs including lungs,
spleen and salivary glands [29], but their role in restricting virus
reactivation in the brain is unclear. B-lineage cells were detected in
the brain as early as 7 d p.i. Similar observations have been made
in other viral brain infections where a surprising number of
CD138
+ cells at 7 d p.i. has been reported [35]. When we assessed
the infiltrating immune cells for production of virus-specific
antibodies by ELISPOT assay, these virus-specific ASCs were
detected for as long as 65 d p.i. Similar trafficking and persistence
of ASC in the CNS has been reported in other RNA virus models
such as West Nile virus and mouse Alpha-virus infections [12,35].
Similar to other members of the herpesviridae, CMVs remain
within their host and establish lifelong latency after primary
infection. Depending on the host and viral system, the question of
whether the virus is truly latent or maintains a low-level, persistent
viral infection has not been completely resolved. Operationally,
latency is defined as the inability to detect replicating virus despite
the presence of virus DNA and perhaps some limited transcrip-
tion. In murine models of MCMV infection, latency is
characterized by the ability to reactivate virus from cells of
infected tissues after cocultivation with permissive cells in culture,
even though infectious virus cannot be detected directly in tissue
homogenates [36,37]. Immunosuppression [38] or immunologic
modulation, such as allogeneic stimulation [39], has been shown to
induce reactivation of latent virus. Results of the studies reported
here support the idea that after MCMV brain infection, virus
becomes latent in neurons and that this latent virus may
subsequently reactivate. In addition to the brain, results from
several studies suggest that MCMV also becomes latent in other
organs, including eye [38], lungs [40] and salivary glands [41].
Earlier studies have also demonstrated that virus recovery from
other latently infected tissues, such as salivary gland and lungs, is
100–1000 fold higher in B-cell deficient mice [29].
Previous reports have suggested that the early gene E1 product
is retained in neurons of MCMV-infected mouse brains [25],
especially during prolonged infection [26], and could, therefore, be
used as a marker of viral latency. These studies utilized neonatal
infection models to demonstrate differential expression of various
gene products in diverse cellular sources. In this study, utilizing the
same monoclonal antibody, we confirmed that E1 expression was
evident in the hippocampal region and, based upon the
morphology of infected cells, it appears that neurons were the
cell type harboring latent viral infection. Interestingly, we failed to
Figure 5. Reactivated infectious virus is recovered more efficiently from the brains of B-cell deficient animals. A. Periventricular brain
tissue obtained from latently-infected animals (.30 d p.i.) was cut into 1 mm pieces and placed onto primary murine glial cell cultures. At 10 d post-
explant, these cultures were stained for MCMV-IE1 expression, indicative of viral reactivation, and processed for real-time PCR (MCMV IE1 and gB
genes). B. Explant reactivation results in Wt versus Jh
2/2 mice as determined using real-time PCR for IE1 and gB, as well as IE1 antigen staining. Data
are shown as the number positive animals over total number examined (+/n). **p,0.01 Jh
2/2 versus Wt animals.
doi:10.1371/journal.pone.0033143.g005
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30 d p.i., possibly due to low copy numbers and detection limits in
the homogenates.
Results presented here demonstrate that humoral immune
responses in the CNS are important in controlling reactivated
virus. Jh
2/2 mice had a higher frequency of virus recovery from
the brain, suggesting that B-cells directly limit viral recovery.
Taken together these results suggest that MCMV infection results
in the recruitment of B-lineage cells into the brain and these cells
play important role in controlling reactivated virus.
Methods
Ethical statement
This study was carried out in strict accordance with recom-
mendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Institutional Animal Care and Use Committee
(Protocol Number: 0807A40181) of the University of Minnesota.
All surgery was performed under Ketamine anesthesia, and all
efforts were made to minimize suffering.
Virus and animals
RM461, a MCMV expressing Escherichia coli b-galactosidase
under the control of the human ie1/ie2 promoter/enhancer [42]
was kindly provided by Edward S. Mocarski. The virus was
maintained by passage in weanling female BALB/c mice. Salivary
gland-passed virus was then grown in NIH 3T3 cells for 2
passages, which minimized any carry over of salivary gland tissue.
Infected 3T3 cultures were harvested at 80% to 100% cytopathic
effect and subjected to three freeze–thaw cycles. Cellular debris
was removed by centrifugation (10006g)a t4 uC, and the virus was
pelleted through a 35% sucrose cushion (in Tris-buffered saline
[50 mM Tris–HCl, 150 mM NaCl, pH 7.4]) at 23,0006g for 2 h
at 4uC. The pellet was resuspended in Tris buffered saline
containing 10%FBS. Viral stock titers were determined on 3T3
cells as 50% tissue culture infective doses (TCID50) per milliliter.
Six to eight weeks old BALB/c mice were obtained from Charles
River Laboratories (Wilmington, MA), while B-cell deficient mice
(Jh
2/2) were a kind gift from Dr. Steven McSorley (University of
California, Davis).
Intracerebroventricular infection
Infection of mice with MCMV was performed as previously
described [5]. Briefly, female mice (6–8 week old) were
anesthetized using a combination of Ketamine and Xylazine
(100 mg and 10 mg/kg body weight, respectively) and immobi-
lized on a small animal stereotactic instrument equipped with a
Cunningham mouse adapter (Stoelting Co., Wood Dale, IL). The
skin and underlying connective tissue were reflected to expose
reference sutures (sagittal and coronal) on the skull. The sagittal
plane was adjusted such that the bregma and lambda were
positioned at the same coordinates on the vertical plane. Virulent,
salivary gland-passaged MCMV RM461 (1.5610
5 TCID50 units
in 10 ml), was injected into the right lateral ventricle at 0.9 mm
lateral, 0.5 mm caudal to the bregma and 3.0 mm ventral to the
skull surface using a Hamilton syringe (10 ml) fitted to a 27 G
needle. The injection was delivered over a period of 3–5 min. The
opening in the skull was sealed with bone wax and the skin was
closed using 9 mm wound clips (Stoelting Co., Wood Dale, IL).
Isolation of brain leukocytes and FACS
Leukocytes were isolated from MCMV-infected murine brains
using a previously described procedure with minor modifications
[21,43,44,45]. In brief, brain tissues harvested from four to six
animals were minced finely in RPMI 1640 (2 g/L D-glucose and
10 mM HEPES) and digested in 0.0625% trypsin (in Ca/Mg-free
HBSS) at room temperature for 20 min. Single cell preparations
from infected brains were resuspended in 30% Percoll and banded
on a 70% Percoll cushion at 9006 ga t1 5 uC. Brain leukocytes
obtained from the 30–70% Percoll interface were treated with Fc
block (anti-CD32/CD16 in the form of 2.4G2 hybridoma culture
supernatant with 2% normal rat and 2% normal mouse serum) to
inhibit nonspecific Ab binding and were stained with anti-mouse
immune cell surface markers for 45 min at 4uC (anti-CD45-
allophycocyanin (eBioscience), anti-CD11b-FITC or anti-CD11b-
APC-CY7, anti-CD19-FITC, anti-CD138-APC, anti-CD38-PE,
and anti-CD3-PE-Cy7 (BD Biosciences)) and analyzed by flow
cytometry. Control isotype Abs were used for all isotype and
fluorochrome combinations to assess nonspecific Ab binding. Live
leukocytes were gated using forward scatter and side scatter
parameters on a BD FACSCanto flow cytometer (BD Biosciences).
Data was analyzed using FlowJo software (TreeStar).
Adoptive transfer
FVB/N luciferase transgenic mice (luciferase expression driven
by the b-actin promoter; Xenogen) were backcrossed for 10
generations into BALB/c mice (Charles River Laboratories) and
were bred in house. Luciferase activity of resulting BALB/c Luc
+
mouse colony was confirmed for 5 generations prior to use. These
BALB/c Luc
+ mice were used as donors in adoptive transfer
experiments. Spleens from MCMV primed (1610
5 TCID50/
mouse, i.p. injection) donor animals were collected aseptically at
7 d post-priming. Single cell suspensions of immunocytes were
depleted of RBC by treatment with 0.87% ammonium chloride,
washed twice, and cell viability was confirmed using trypan blue.
CD19
+ lymphocytes were enriched by negative selection using a
CD19
+ cell purification kit, as per the manufacturer’s instructions
(R&D systems, Minneapolis, MN USA). Immune cells were
transferred (5610
6 cells/mouse) via tail vein 1 d prior to infection
with MCMV into syngenic (Jh
2/2) recipients.
Bioluminescence imaging
Imaging of firefly luciferase expression in live animals was
performed using an IVIS50 (Xenogen) equipped with a charge-
coupled camera device, as previously described with minor
modifications [46]. In brief, 150 mg of D-luciferin (Gold
Biotechnology) was administered to anesthetized mice by i.p.
injection. Animals were imaged 5 min after D-luciferin adminis-
tration and data were acquired using a 5-min exposure window.
Bioluminescence imaging studies were conducted with age-
matched 8- to 10-wk-old female Jh
2/2 mice as recipients and
MHC-matched female BALB/c luciferase transgenic mice as
leukocyte donors. Immune cells were derived from the spleens of
MCMV primed animals. The enriched CD19
+ lymphocyte
population was used for the adoptive transfer experiments.
Immunohistochemistry to detect MCMV-E1 or IE1,
CD138, IgG and IgM
Brains were harvested from infected mice that were perfused
with serial washes of 2% sodium nitrate and phosphate-buffered
saline (PBS) to remove contaminating blood cells and prefixed
with 4% paraformaldehyde. Murine brains were subsequently
submerged in 4% paraformaldehyde for 24 h and transferred to
30% sucrose solution for 2 d. After blocking (16 PBS, 10%
normal goat serum and 0.3% Triton X-100) for 1 h at room
temperature, brain sections (25 mm) were incubated overnight at
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(Syndecan-1, a plasma cell marker), (1:100; BD Biosciences,
Franklin Lakes, NJ), biotinylated goat anti-mouse IgG and Ig53M
(1:600; Jackson ImmunoResearch Laboratories, West Grove, PA),
MCMV IE1-specific monoclonal antibody (MAb Croma 101,
kindly provided by Dr. Stipan Jonjic, University of Rijeka,
Croatia), monoclonal anti-E1 antibody (MAb kindly provided by
Dr. I Kosugi, Hamamatsu University, Japan). Brain sections were
washed three times with PBS and then incubated with fluorescein
(FITC)–conjugated anti rat antibody (1:200; Vector Laboratories,
Burlingame,CA), or Cy3- conjugated streptavidin (1:400; Jackson
ImmunoResearch Laboratories) for 1 h at RT. Virus-specific
antigen were detected using an immunoperoxidase method. After
a 5 min pretreatment with 0.3% H2O2, a subset of sections from
each animal was incubated with primary antibodies overnight at
4uC. The sections were then rinsed and incubated for 1 h in
biotinylated goat anti-mouse (Vector Laboratories). The goat anti-
mouse biotinylated antibody was reacted with an avidin-HRP
conjugate. The HRP chromagen was developed using diamino-
benzidine (DAB) substrate (Vector Laboratories). Sections were
counterstained with Mayer’s hematoxylin.
Real-time PCR
Total RNA was extracted from brain tissue homogenates using
the Trizol reagent (Invitrogen, Carlsbad, CA). One mg RNA was
DNase (Ambion, Applied Biosystems, Austin, TX) treated and
reverse transcribed to cDNA with SuperScript
TM III (Invitrogen),
dNTP (GE Healthcare, Piscataway, NJ) and oligo (dT)12–18
(Promega, Madison, WI). Real-time PCR was performed in an
Mx3000p (Stratagene, La Jolla, CA) with SYBR Advantage qPCR
Premix (Clontech, Mountain View, CA), primers and cDNA
according to the manufacturer’s protocol. Reaction conditions for
qPCR were as follows: initial denaturation at 95uC for 15 sec,
amplification for 40 cycles at 95uC for 10 sec, 60uC for 10 sec and
72uC for 10 sec followed by dissociation curve analysis (1 cycle at
95uC for 60 sec, 55uC for 30 sec and 95uC for 30 sec) to verify
product specificity. After normalizing to HPRT-1 expression
(DCt=target gene Ct2HPRT Ct) and then to the control group
(DDCt=treatment DCt2C DCt), relative quantification using
2‘2DDCt was calculated as fold change of target mRNA expression
vs. control. Primer sequences for MCMV IE1 [10], mAPRIL,
BAFF, and IL-21 [13] were obtained from published literature.
ELISPOT assay for ASC
ELIPOT for ASC isolated from the brain was performed using
previously published methods [35]. Briefly, plates (96-well
nitrocellulose; Millipore, Billerica, MA) were coated with serum-
free MCMV (1610
6 TCID50/well) or conditioned medium
(irrelevant antigen) and then blocked with RPMI plus 10% FBS.
Mononuclear cells were isolated from the brains of MCMV-
infected mice as described above, added to wells (2610
5 cells/well)
in triplicate, and incubated overnight. ASC spots were developed
by sequential addition of biotinylated anti-IgG (Vector Laborato-
ries, Burlingame, CA), horseradish peroxidase-conjugated strepa-
vidin (Vector Laboratories), and 3-amino-9-ethyl carbazole
substrate (BD Biosciences) and counted using a dissecting
microscope. The numbers of specific ASC were determined by
subtraction of the average number of spots in the irrelevant
antigen wells (range: 0–5) from the average number of spots in the
MCMV-specific antigen wells.
Ex vivo reactivation assay
Brains were isolated from latently infected BALB/c and Jh
2/2
mice and 1 mm coronal sections were cut using a precision brain
matrix (Braintree Scientific, Braintree, MA, USA). The coronal
sections were then cut around the ventricles; ,25 pieces were
collected from each brain that represented tissue adjoining lateral
and central ventricles. 3–4 pieces were then inoculated onto
previously prepared primary mouse brain cultures in a 12-well
plate. The cultures were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum and
antibiotics. The cultures were analyzed microscopically for the
occurrence of cytopathic effect. Half of the wells containing
primary mouse brain culture cells infected with the recovered
viruses were analyzed by immunostaining using monoclonal
antibodies Croma101 (anti-MCMV IE1) and a secondary
horseradish peroxidase-conjugated anti-mouse antibody (Dako,
Hamburg, Germany). The remaining wells were used for RNA
isolation and real-time PCR detection of MCMV-IE1 and gB gene
expression.
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